Pakistan has the highest multidrug-resistant (MDR) tuberculosis (TB) burden in the Eastern Mediterranean region of the World Health Organization (WHO) (12). Fluoroquinolones (FQ) are an integral component of second-line therapy for multidrug-resistant strains (11). FQ resistance among Mycobacterium tuberculosis strains is reported in regions with high quinolone usage (1). Such regions also include Pakistan, with over-thecounter antimicrobial prescriptions and extensive FQ usage (2). National TB surveillance data to assess prevalence of FQ resistance in the country are not available. The current study was conducted to determine FQ resistance in M. tuberculosis at a community level.
Pakistan has the highest multidrug-resistant (MDR) tuberculosis (TB) burden in the Eastern Mediterranean region of the World Health Organization (WHO) (12) . Fluoroquinolones (FQ) are an integral component of second-line therapy for multidrug-resistant strains (11) . FQ resistance among Mycobacterium tuberculosis strains is reported in regions with high quinolone usage (1) . Such regions also include Pakistan, with over-thecounter antimicrobial prescriptions and extensive FQ usage (2) . National TB surveillance data to assess prevalence of FQ resistance in the country are not available. The current study was conducted to determine FQ resistance in M. tuberculosis at a community level.
Methods. This study was conducted in Karachi, the largest city in Pakistan. Our study sites included 10 field clinics run by the Marie Adelaide Leprosy Centre (MALC), a nongovernmental organization working in partnership with the government of Pakistan. These clinics, within Karachi, are located in low-socioeconomic, highly populated administrative units. Patients are either self-referred or referred by their nearby general practitioners. The prevalence of FQ resistance was estimated through a study of consenting adult patients with a clinical suspicion of pulmonary TB at initial enrollment.
Early-morning sputum specimens were collected and transported to the clinical laboratory of the Aga Khan University Hospital (AKUH) for smear examination, culture, and drug susceptibility testing (DST). AKUH laboratory is accredited by the Joint Commission of International Accreditation (JCIA) and by World Health Organization (WHO) Supranational Laboratory external quality assurance for first-and second-line drug susceptibility testing.
Both LJ and MGIT (Becton Dickinson) were used for the isolation of M. tuberculosis for all specimens. M. tuberculosis was identified by the Bactec NAP TB differentiation test (Becton Dickinson), growth in p-nitrophenyl butyrate (PNB)-containing medium, nitrate reduction, and niacin accumulation (10) . Susceptibility testing was performed using the agar proportion method on enriched Middlebrook 7H10 medium (BBL) at the following concentrations: rifampin (R), 1 g/ml; isoniazid (H), 0.2 g/ml and 1 g/ml; and ethambutol (E), 5 g/ml. Pyrazinamide (Z) sensitivity was carried out using the Bactec 7H12 medium (pH 6.0) at 100 g/ml (Bactec PZA test medium, Becton Dickinson) (9) . FQ susceptibilities were determined with ciprofloxacin (2 g/ml) from 2006 to 2008 and with ofloxacin (2 g/ml) from 2009 onward (9) . M. tuberculosis H37Rv was used as a control with each batch of susceptibility testing. MDR was defined as resistance to both isoniazid (0.2 g/ml) and rifampin.
Spoligotyping was performed on all FQ-resistant strains using a commercially available kit provided by Isogen Life Science B.V., Maarssen, Netherlands. DNA was extracted by the cetyltrimethylammonium bromide (CTAB) method (6) . Spoligotyping based on the 43 spacers of the direct repeat (DR) region of the M. tuberculosis complex was carried out using primers DRa (5Ј GGTTTTGGGTC TGACGAC 3Ј) and DRb (5Ј CCGGAGAGGGGACGGAAAC 3Ј) as originally described (8) . Negative and positive controls, including template-free PCR-amplified reaction mix and M. tuberculosis H37Rv DNAs, were used with each spoligotype blot. The spoligotyping results were entered in the BioNumerics software version 3.5 Applied Maths Program, Biosystematica, United Kingdom. A dendrogram was generated using the unweighted pair group method with arithmetic averages (UPGMA) calculation. The spoligotypes were compared with the most prevalent M. tuberculosis subfamilies, as identified by the world spoligotyping database, SpolDB4.0, of Pasteur Institute of Guadeloupe (http://www.pasteur-guadeloupe.fr /tb/bd_myco.html), including Ͼ40,000 isolates split into 1,030 shared types and Ͼ3,530 orphan profiles (5) .
Data management and statistical analysis. Data were double entered into an Epi database and checked for errors and were then transferred to statistical software SPSS version 16.0. Duplicate specimens from the same patients were excluded. Frequencies with percentages were computed for each category.
Results and discussion. Fluoroquinolone susceptibility was checked in 205 patients. Of these, 53 (25.9%) had a history of previous treatment with first-line antituberculous drugs (isoniazid, rifampin, ethambutol, and pyrazinamide). Fluoroquinolones as antituberculous agents were not included in any of the patients' regimes. All patients gave a history of receiving multiple courses of antibiotics during the course of their current illness; however, due to an absence of centralized pharmacy records, this could not be further evaluated.
Of the 205 strains included, 5.9% (n ϭ 12) were resistant to fluoroquinolones. The rate of resistance was highest among MDR strains (11.1% [n ϭ 5]), followed by strains with resistance to Ն2 first-line drugs (6.5% [n ϭ 2]). FQ resistance (4.9% [n ϭ 5]) was also detected among strains fully sensitive to first-line drugs (Table 1) . FQ resistance among previously treated and untreated groups did not differ significantly (9.4% versus 4.6%; P value of 0.206). FQ resistance was significantly higher in patients with durations of illness of more that 3 months (18.8% versus 3.5%; P value of 0.004). Spoligotyping of 10/12 FQ-resistant strains did not show dominance of any one particular strain type within these isolates (Table 2) .
Our data indicating FQ resistance among both MDR strains and strains sensitive to first-line agents reflect high FQ usage, a hypothesis supported by increasing FQ resistance in other bacterial pathogens from this area (7, 13) . While FQs were not used in TB treatment, data of FQ usage in our patients prior to enrollment for TB treatment were not available; however, FQ is reported to be one of the most commonly used antibiotics in Pakistan for many indications (2). Moreover, significantly higher rates of resistance in patients with illness durations of more than 3 months also point to the possibility of multiple FQ prescriptions in these patients for indications other than tuberculosis.
The lack of association between FQ resistance and strain type argues against a role of particular genotypes in the dissemination of resistant strains in the community and argues for the concept of usage-driven resistance. This is in contrast to an earlier study reporting high rates of FQ resistance among specific strain types (4) . Our data therefore point to an urgent need to control FQ usage in this community.
In general terms, a resistance rate of more than 5% renders an agent unsuitable for use as an empirical drug in the management of tuberculosis (3). To date, there are no guidelines for FQ testing other than as a second-line agent in treatment failure cases. We therefore recommend that in areas with high rates of FQ resistance, such as ours, FQ testing should be considered part of first-line DST and included in rapid diagnostics for the detection of resistant strains. 
